V
Viridian Therapeutics D
D
VRDN
14.720
USD
-0.28
(-1.83%)
مغلق
حجم التداول
16,001
الربح لكل سهم
-4
العائد الربحي
-
P/E
-4
حجم السوق
1,201,034,623
الأخبار المقالات
العنوان: Viridian Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly knownas VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).